Journal
CLINICAL CHEMISTRY
Volume 54, Issue 10, Pages 1608-1616Publisher
AMER ASSOC CLINICAL CHEMISTRY
DOI: 10.1373/clinchem.2008.108175
Keywords
-
Categories
Funding
- NIH Clinical Center
- Department of Health and Human Services
- National Cancer Institute's Clinical Proteomic Technology Assess for Cancer Program [U24-CA126476]
- NATIONAL CANCER INSTITUTE [U24CA126476] Funding Source: NIH RePORTER
- CLINICAL CENTER [Z01CL010342] Funding Source: NIH RePORTER
Ask authors/readers for more resources
CONTENT: We surveyed proteomic studies to identify candidates for high-abundance polypeptide chains. We searched the literature for information on the plasma concentrations of the most abundant components in healthy adults and for the molecular mass of the mature polypeptide chains in plasma. Because proteomic studies usually dissociate proteins into polypeptide chains or detect short peptide segments of proteins, we summarized data on individual peptide chains for proteins containing multiple subunits or polypeptides. We collected data on about 150 of the most abundant polypeptides in plasma. The abundant polypeptides span approximately the top 4 logs of concentration in plasma, from 650 to 0.06 mu mol/L on a molar basis or from about 50 000 to 1 mg/L mass abundance. CONCLUSIONS: Data on the concentrations of the high-abundance peptide chains in plasma assist in understanding the composition of plasma and potential approaches for clinical laboratory or proteomic analysis of plasma proteins. Development of more extensive databases regarding the plasma concentrations of proteins in health and diseases would promote diagnostic and proteomic advances. (c) 2008 American Association for Clinical Chemistry.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available